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Abstract 
Background: The study aimed to investigate the expression changes of genes in colorectal cancer (CRC) and screen 
the potential molecular targets.
Methods: The GSE37178 of mRNA expression profile including the CRC samples extracted by surgical resection and 
the paired normal samples was downloaded from Gene Expression Omnibus database. The genes whose expres-
sions were changed at four different time points were screened and clustered using Mfuzz package. Then DAVID was 
used to perform the functional and pathway enrichment analysis for genes in different clusters. The protein–protein 
interaction (PPI) networks were constructed for genes in the clusters according to the STRING database. Furthermore, 
the related-transcription factors (TFs) and microRNAs (miRNAs) were obtained based on the resources in databases 
and then were combined with the PPI networks in each cluster to construct the integrated network containing genes, 
TFs and miRNAs.
Results: As a result, 314 genes were clustered into four groups. Genes in cluster 1 and cluster 2 showed a decreasing 
trend, while genes in cluster 3 and cluster 4 presented an increasing trend. Then 18 TFs (e.g., TCF4, MEF2C and FOS) 
and 18 miRNAs (e.g., miR-382, miR-217, miR-1184, miR-326 and miR-330-5p) were identified and three integrated 
networks for cluster 1, 3, and 4 were constructed.
Conclusions: The results implied that expression of PITX2, VSNL1, TCF4, MEF2C and FOS are time-related and associ-
ated with CRC development, accompanied by several miRNAs including miR-382, miR-217, miR-21, miR-1184, miR-
326 and miR-330-5p. All of them might be used as potential diagnostic or therapeutic target molecules for CRC.
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Background
Colorectal cancer (CRC) is the third most common can-
cer worldwide with over 1,000,000 new cases every year 
[1]. In China, CRC is ranked as the fourth leading cause 
of cancer death with a pronounced increasing incidence 
during recent years [2]. Reportedly, the main risk fac-
tors for CRC include dietary and lifestyle factors, such 
as diet, obesity, physical activity, smoking and alcohol 
abuse [3–5]. Moreover, accumulating evidence indicate 
that multiple molecules are involved in CRC [6, 7]. For 
instance, CARM1 has been linked to human CRC by 
modulating Wnt/β-catenin transcription and neoplas-
tic transformation [8]. Several microRNAs (miRNAs) 
are also involved in the occurrence and development of 
CRC, such as miR-31, miR-126, miR-552, miR-592 and 
miR-224 [9, 10]. Moreover, p53-dependent expression 
of miR-34a is reported to suppress CRC progression by 
inhibiting an IL-6R/STAT3/miR-34a feedback loop [11]. 
More recently, utilizing the expression profile dataset of 
GSE44861, Wang et  al. investigated the regulatory rela-
tionships between miRNAs and the target genes in CRC, 
and consequently identified a handful of crucial miRNAs 
such as miR-29 (with the putative target of COL11A1), 
miR-101 and miR-26 (both with the predicted targets of 
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PTGS2 and ASPN) [12]. However, pathogenesis of the 
cancer remains obscure.
Currently, time course gene expression is an increas-
ingly popular approach for researching a wide range of 
biological processes (BPs) [13]. Recently, Musella et  al. 
[14] have analyzed the gene expression profiling in 
human normal and CRC tissues at four time points after 
routine surgical procedure. They have identified several 
time-dependent genes in tumor and normal samples, 
such as JUN, FOSB and ABL1. However, they put empha-
sis on determining the critical time point for tissue han-
dling in colon before which the gene alterations are not 
detected. Gene alteration trends during the whole period 
are not investigated. Besides, the potential interactions of 
the genes and the regulatory relationships between these 
genes and the related transcription factors (TFs) or miR-
NAs are not explored.
Therefore, we further investigated the mRNA expres-
sion profile of patients with CRC at four time points by 
re-analyzing the data of Musella et  al. [14] which were 
deposited in Gene Expression Omnibus (GEO) data-
base. The genes whose expressions were changed during 
different periods were screened and clustered. Then the 
gene ontology (GO) and kyoto encyclopedia of genes and 
genomes (KEGG) enrichment analyses were performed 
for genes in different clusters. Furthermore, the protein–
protein interaction (PPI) networks were constructed and 
the TFs and miRNAs were screened based on the infor-
mation in the relevant databases. Moreover, an integrated 
PPI-TF-miRNA regulatory network was established in 
each cluster. Our study sought to explore the changes of 
the critical time-related genes in CRC with potential reg-
ulators such as miRNAs and TFs, and provide evidence 
for molecular targets therapy of CRC.
Methods
Microarray data
The mRNA expression profile of GSE37178 was down-
loaded from GEO database (http://www.ncbi.nlm.nih.
gov/geo/) deposited by Musella et  al. [14]. The paired 
tumor and normal specimens collecting from 14 patients 
who underwent surgical resection at the INT-MI (Fon-
dazione IRCCS Istituto Nazionale dei Tumori) were 
utilized in our study. The tumor specimens were all clas-
sified as moderately differentiated colonic Adenocarci-
nomas NOS, namely grade G2 basing on the American 
Joint Committee on Cancer 2010 (http://www.cancer-
staging.org/) by the histological routinely examination 
[14]. The RNAs were extracted from the above patients. 
Six fragments from each patient were acquired and were 
randomly left at room temperature at four time points as 
follows: three fragments at <20 min (T0), one fragment at 
60 min (T1), one fragment at 180 min (T2) and one frag-
ment at 360 min (T3). Time was measured starting from 
patient’s surgical excision and the first time point (T0) 
was processed and frozen within 20  min from surgery. 
The control samples were the matched normal tissue at 
four time points after surgery [14]. In Musella’s study, all 
patients signed an informed consent and the experiments 
were approved by the Independent Ethical Committee of 
the INT-MI.
Preprocessing of the raw data
Raw data were collected with Illumina Human HT-12 
V3.0 expression beadchip (Illumina Inc, San Diego, CA, 
USA) and were preprocessed via background correction, 
quantile normalization and probe summarization using 
the LIMMA (Linear Models for Microarray Data, http://
www.bioconductor.org/packages/release/bioc/html/
limma.html) package [15] in R. Then the probe-level val-
ues in CEL files were converted into the mRNA expression 
values.
Clustering analysis
The noise-robust soft clustering was performed for the 
samples in four time groups using Mfuzz package (http://
www.bioconductor.org/packages/release/bioc/html/
Mfuzz.html, version 2.6.1) [16]. According to the changes 
of gene expression at four different time points, genes 
were clustered into different groups. The default param-
eters were as follows: minimum standard deviation = 0.3, 
acore = 0.6.
GO and KEGG pathway enrichment analysis
The DAVID (The Database for Annotation, Visualiza-
tion and Integrated Discovery, http://david.abcc.Ncifcrf.
gov/) online tool [17] was used to identify the over-repre-
sented GO categories in different BPs and the significant 
KEGG pathways for the genes in different clusters. The p 
value < 0.05 and gene count ≥ 2 were used as cut-off cri-
teria for the selection of significant GO terms and KEGG 
pathways.
Screening of transcription factors (TFs) 
and tumor‑associated genes (TAGs)
The TFs were identified amongst the clustered gene sets 
according to the TRANSFAC database (http://www.
gene-regulation.com/pub/databases.html), which col-
lects eukaryotic TFs and their binding sites, as well as the 
DNA binding profiles [18]. Furthermore, oncogenes and 
tumor suppressor genes (TSGs) were also obtained from 
the gene sets by using the TSGene database (http://bio-
info.mc.vanderbilt.edu/TSGene/) [19] and TAG database 
(http://www.binfo.ncku.edu.tw/TAG/) [20].
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Network construction
The STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins, http://string-db.org/) database [21] was 
used to analyze PPIs for genes with the cut-off criterion 
of combined score >0.4 and the PPI network was then 
visualized by cytoscape (http://cytoscape.org/) software 
[22]. The protein product of a gene serves as a node in 
the PPI network, and the degree denotes the interplayed 
protein numbers of the specific protein. A node with high 
degrees is deemed as a hub node. By analyzing the con-
nectivity degrees of the nodes in PPI networks, the hub 
proteins were obtained. Meanwhile, according to the 
miRNA-related databases such as miRanda (http://www.
microrna.org/microrna/home.do), MirTarget2 (http://
mirdb.org/miRDB/), PicTar (http://pictar.org/), PITA, 
TargetScan (http://www.targetscan.org/) and miRecords 
(http://mirecords.biolead.org/), the miRNAs which 
might regulate the genes were obtained with the cut-
off criterion of p value  <0.05. Then the miRNA-mRNA 
regulatory networks were constructed. Furthermore, 
based on the information in the ENCODE (encyclope-
dia of DNA elements) database (http://genome.ucsc.edu/
ENCODE/), [23] the TF-target regulatory network was 
constructed. Finally, an integrated network combining 
the PPI network, miRNA-mRNA regulatory network and 




With the aforementioned cut-off criteria, four gene 
sets were obtained. Among which, a downward expres-
sion trend with the increasing time for genes in cluster 1 
(35 genes) and cluster 2 (53 genes) was observed, while 
an upward expression trend was presented in cluster 3 
(121 genes) and cluster 4 (105 genes) (Fig. 1). In cluster 
1, expressions of the genes were almost stable from T0 
to T2, while were downward obviously from T2 to T3. In 
cluster 2, the expressions tended to be stable from T0 to 
T1, decreasing from T1 to T2, and then leveling out from 
T2 to T3. In contrast to cluster 1, expressions of genes in 
cluster 3 were stable from T0 to T2, while increasing from 
T2 to T3. In cluster 4, the expressions kept stable from T0 
to T1 and were then increasing remarkably from T1 to T3.
GO and KEGG enrichment analysis
The GO enrichment results showed that the genes in 
four clusters were enriched in 13, 5, 133 and 119 GO 
terms, respectively. The top ten GO terms in each clus-
ter are listed in Table 1. Meanwhile, the enriched KEGG 
pathways of the genes in cluster 1, 3, and 4 were shown 
in Table  2. The results demostrated that metabolism 
of xenobiotics by cytochrome P450 (P  =  9.06E−02), 
intestinal immune network for IgA production 
(P  =  2.24E−08) and systemic lupus erythematosus 
(P = 5.81E−07) were the predominant KEGG pathways 
for genes in cluster 1, 3 and 4, respectively. Genes in clus-
ter 2 were not enriched in any significant pathway.
Identification of oncogenes, TSGs and TFs amongst the 
selected genes
Basing on the relevant information in the aforemen-
tioned databases, potential oncogenes, TSGs and TFs 
amongst the selected genes in four clusters were revealed. 
As shown in Table 3, in cluster 1, ETV4, MSX2, PITX2, 
SMAD9 were identified as TFs; CUL7 was as a TSG and 
KLK6 was an oncogene. In cluster 2, CEACAM7, DEFB1, 
MUC1 and SLC26A3 were considered as TSGs. In clus-
ter 3, EOMES, HEY2, HHEX, MEF2C, POU2AF1, STAT4, 
TCF21 and TCF4 were TFs; AIM2, BEX2, MAP4K1, 
PEG3, PRICKLE1, PYHIN1 and TCF4 were TSGs. In 
cluster 4, ATF3, DBP, HAND1, KLF2, MAFB and SOX18 
were TFs and FOS was an oncogene.
Screening of miRNAs
With the predefined selection criteria, several miR-
NAs which could target the genes were predicted. The 
results indicated that three miRNAs were predicted 
to target genes in cluster 1: hsa-miR-382 could target 
CLDN1, DLX3 and IRX3; hsa-miR-217 could modeu-
late DMRT2, MSX2, SMAD9 and VSNL1; hsa-miR-21 
could regulate PITX2 and VSNL1. In cluster 3, five miR-
NAs were obtained: EOMES and RELN were targeted by 
hsa-miR-935; HET2 and TCF4 were regulated by hsa-
miR-1184; C16orf45, HLA-DOA, PKIA, PTGIS, SPOCK1 
and TCF4 were targeted by hsa-miR-326. In cluster 4, ten 
miRNAs were obtained and the top three were hsa-miR-
338-5p (the targets included EBF3, KLF2 and LDB2), 
hsa-miR-656 (the targets included COLEC12, DUSP1 
and TEK) and hsa-miR-30d (the targets included CYYR1, 
EBF3 and EMCN) (Table 4).
Analysis of integrated networks
In order to explore the relationships among the genes, the 
PPI networks for genes in four clusters were constructed. 
As presented in Fig. 2, the network of cluster 1 contained 
7 nodes and 4 PPIs; cluster 2 consisted of 11 nodes and 
7 PPIs; cluster 3 contained 70 nodes and 219 PPIs; while 
cluster 4 comprised of 65 nodes and 187 PPIs. The hub 
nodes in four cluster were PITX2, PCYT1A, CD4 and 
FOS, respectively. Futhermore, the TF and miRNA regu-
latory networks were also constructed, respectively. The 
intergrated PPI-TF-miRNA networks were established 
for the genes in four clusters except in cluster 2, which 
did not contain the pronounced TFs and miRNAs. In the 
integrated network cluster (Int-c) 1, miR-217, miR-21, 
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miR-382 and their respective target genes (e.g., PITX2, 
VSNL1 and DLX3) were interacted with the PPI net-
work in cluster 1 (Fig.  3a). In the Int-c3 network, five 
miRNAs (e.g., miR-935, miR-1184 and miR-326) and 
two TFs (MEF2C and TCF4) were integrated with the 
PPI network in cluster 3. The Int-c3 network showed 
that MEF2C could regulate 17 genes, such as ITGAL, 
CORO1A and SGCA; TCF4 could modulate 15 genes, 
such as LAPTM5, FYB, and CYBRD1 (Fig.  3b). In the 
Int-c4 network, ten miRNAs (e.g., miR-338-5p, miR-656 
and miR-30d) and two TFs (FOS and ATF3) were inte-
grated with the PPI network in cluster 4. It was indicated 
that FOS could regulate 43 genes, such as ATF3, IL6 and 
HIST1H2BC; ATF3 could modulate three genes, includ-
ing GADD45B, DUSP1 and RGS2 (Fig. 3c).
Discussion
In order to further investigate the pathogenesis and 
explore the molecular therapeutic methods for CRC, 
we re-analyzed the mRNA expression of CRC tissues 
extracted after surgical resection at four time points 
and screened a set of time-related genes, such as PITX2 
(paired-like homeodomain 2), VSNL1 (visinin-like 
1), TCF4 (transcription factor 4), MEF2C (myocyte 
enhancer factor 2C) and FOS (FBJ murine osteosarcoma 
viral oncogene homolog). Meanwhile, TCF4, MEF2C 
Fig. 1 The gene expression changes in four clusters. The color varying from green to red represents that the trends of genes become more suitable 
to the changes of the cluster
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and FOS were found to be TFs that have many target 
genes. Besides, a set of miRNAs such as miR-382, miR-
217, miR-21, miR-1184, miR-326 and miR-330-5p were 
obatined.
In this study, the screened genes were classified into 
four clusters according to the gene expression change 
trends. Genes in cluster 1 and cluster 2 showed a decreas-
ing trend during the period from T2 to T3, and from T1 
to T2, respectively. In Int-c1 network, miR-382, miR-217 
and miR-21 were shown to target several genes, such as 
PITX2 and VSNL1.
PITX2, the hub node in PPI network 1, is shown to be 
involved in various functions such as tissue development 
by controlling cell growth in CRC [24]. Upregulation of 
VSNL1 is an indicator of lymph node metastasis and poor 
prognosis in patients with CRC [25]. Another study also 
detects the elevated PITX2 and VSNL1 in CRC samples 
[26]. MiR-21, which is upregulated in many tumours, was 
predicted to target PITX2 and VSNL1 in our study. It has 
been found that plasma miR-21 is a potential diagnostic 
marker of CRC [27, 28]. The results collectively suggested 
that PITX2 and VSNL1 might be both the targets of 
Table 1 Enrichment analysis of top ten GO terms for genes in four clusters
GO gene ontology
Term Count P value Genes
Cluster 1 GO: 0006355~regulation of transcription, DNA-dependent 8 4.53E−02 PITX2, MSX2, DLX3, IRX3, ZNF181, SMAD9, DMRT2, ETV4
GO: 0051252~regulation of RNA metabolic process 8 5.03E−02 PITX2, MSX2, DLX3, IRX3, ZNF181, SMAD9, DMRT2, ETV4
GO: 0016337~cell–cell adhesion 3 9.79E−02 REG3A, CLDN1, CDH3
GO: 0030574~collagen catabolic process 2 3.78E−02 KLK6, MMP7
GO: 0044243~multicellular organismal catabolic process 2 4.88E−02 KLK6, MMP7
GO: 0032963~collagen metabolic process 2 5.25E−02 KLK6, MMP7
GO: 0044259~multicellular organismal macromolecule metabolic 
process
2 5.80E−02 KLK6, MMP7
GO: 0044236~multicellular organismal metabolic process 2 6.88E−02 KLK6, MMP7
GO: 0042552~myelination 2 7.06E−02 KLK6, CLDN1
GO: 0007272~ensheathment of neurons 2 7.77E−02 KLK6, CLDN1
Cluster 2 GO: 0007586~digestion 3 2.69E−02 CAPN9, TFF2, TFF1
GO: 0002526~acute inflammatory response 3 3.08E−02 SERPINA1, C4BPA, LBP
GO: 0010038~response to metal ion 3 5.07E−02 XDH, SERPINA1, TFF1
GO: 0045087~innate immune response 3 5.72E−02 C4BPA, LBP, DEFB1
GO: 0008544~epidermis development 3 9.41E−02 COL17A1, LAMA3, RBP2
Cluster 3 GO: 0006955~immune response 30 3.03E−15 ITGAL, IL16, LY86
GO: 0045321~leukocyte activation 16 1.67E−10 ITGAL, CD3G, TNFSF4
GO: 0001775~cell activation 16 1.79E−09 ITGAL, CD3G, TNFSF4
GO: 0006952~defense response 16 3.00E−05 ITGAL, TNFSF4, AIF1
GO: 0042110~T cell activation 15 2.58E−13 ITGAL, CD3G, TNFSF4
GO: 0046649~lymphocyte activation 15 1.35E−10 ITGAL, CD3G, TNFSF4
GO: 0008283~cell proliferation 11 1.12E−03 HHEX, STAT4, DOCK2
GO: 0042127~regulation of cell proliferation 11 5.52E−02 HHEX, CORO1A, TNFSF4
GO: 0007610~behavior 10 6.45E−03 CORO1A, DOCK2, IL16
GO: 0009611~response to wounding 10 1.37E−02 ITGAL, TNFSF4, AIF1
Cluster 4 GO: 0006334~nucleosome assembly 9 3.17E−08 HIST2H2AA3, HIST4H4, HIST1H1E
GO: 0031497~chromatin assembly 9 4.19E−08 HIST2H2AA3, HIST4H4, HIST1H1E
GO: 0065004~protein-DNA complex assembly 9 5.98E−08 HIST2H2AA3, HIST4H4, HIST1H1E
GO: 0034728~nucleosome organization 9 7.10E−08 HIST2H2AA3, HIST4H4, HIST1H1E
GO: 0006323~DNA packaging 9 4.24E−07 HIST2H2AA3, HIST4H4, HIST1H1E
GO: 0007155~cell adhesion 18 5.34E−07 EMCN, NRP1, CCL2
GO: 0022610~biological adhesion 18 5.45E−07 EMCN, NRP1, CCL2
GO: 0006333~chromatin assembly or disassembly 9 7.96E−07 HIST2H2AA3, HIST4H4, HIST1H1E
GO: 0009611~response to wounding 14 1.26E−05 C3AR1, CCL3, IL6
GO: 0001568~blood vessel development 9 9.73E−05 VEGFC, EMCN, NRP1
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miR-21 in CRC, and it might be the suppression of miR-
21 that result in the downregulation of the two genes in 
our present study. In other cancers such as breast cancer 
and non small cell lung cancer, PITX2 is also predicted as 
a target of miR-21, [29, 30] strengthening the reliability of 
our predictions and our faith to validate these targeting 
relationships in the follow-up studies using dual-lucif-
erase reporter assay.
Besides, miR-382 was shown to target CLDN1 (clau-
din 1), DLX3 (distal-less homeobox  3) and IRX3 (iro-
quois homeobox  3); miR-217 could regulate VSNL1, 
MSX2 (msh homeobox 2), DMRT2 (doublesex and mab-3 
related transcription factor 2) and SMAD9 (SMAD fam-
ily member 9). Most of the targets were enriched in the 
GO terms of “regulation of transcription, DNA-depend-
ent” and “regulation of RNA metabolic process”, indicat-
ing that the two BPs were mainly inhibited by miR-382 
and miR-217.
Meanwhile, genes in cluster 3 and cluster 4 showed 
an increasing trend during the period from T2 to T3, and 
from T1 to T3, respectively. In cluster3, TCF4 was identi-
fied as an important TF, which regulated 15 genes, such 
as C16orf45 (chromosome 16 open reading frame 45) and 
RASGRP3 (RAS guanyl releasing protein 3 (calcium and 
DAG-regulated)). C16orf45 was also targeted by miR-326 
and miR-330-5p, and RASGRP3 was regulated by miR-496. 
Besides, TCF4 was also the target gene of miR-1184, miR-
326 and miR-330-5p. It is found that the β-catenin/TCF4 
Table 2 Enriched KEGG pathways for genes in four clusters
KEGG Kyoto encyclopedia of genes and genomes
Term Count P‑value Genes
Cluster 1 hsa00980: Metabolism of xenobiotics by cytochrome P450 2 9.06E−02 CYP3A7, ALDH3B2
hsa00982: Drug metabolism 2 9.35E−02 CYP3A7, ALDH3B2
Cluster 3 hsa04672: Intestinal immune network for IgA production 9 2.24E−08 TNFSF13B, CXCR4, ICOS
hsa04514: Cell adhesion molecules (CAMs) 9 4.80E−05 ITGAL, SELL, ICOS
hsa04060: Cytokine-cytokine receptor interaction 9 4.66E−03 IL2RB, TNFSF4, TNFSF13B
hsa05416: Viral myocarditis 8 6.22E−06 ITGAL, MYH11, HLA-DPA1
hsa04062: Chemokine signaling pathway 7 1.14E−02 DOCK2, CCL21, CXCR4
hsa05340: Primary immunodeficiency 6 2.37E−05 CD3D, ICOS, TNFRSF13B
hsa04640: Hematopoietic cell lineage 6 1.71E−03 CD37, CD3G, CD3D
hsa04660: T cell receptor signaling pathway 6 4.63E−03 CD3G, CD3D, ICOS
hsa05330: Allograft rejection 5 4.50E−04 HLA-DPA1, HLA-DPB1, HLA-DOA
hsa05332: Graft-versus-host disease 5 6.14E−04 HLA-DPA1, HLA-DPB1, HLA-DOA
hsa04940: Type I diabetes mellitus 5 8.17E−04 HLA-DPA1, HLA-DPB1, HLA-DOA
hsa05320: Autoimmune thyroid disease 5 1.70E−03 HLA-DPA1, HLA-DPB1, HLA-DOA
hsa04612: Antigen processing and presentation 5 9.86E−03 CD4, HLA-DPA1, HLA-DPB1
hsa05322: Systemic lupus erythematosus 5 1.79E−02 HLA-DPA1, HLA-DPB1, HLA-DOA
hsa05310: Asthma 4 3.06E−03 HLA-DPA1, HLA-DPB1, HLA-DOA
Cluster 4 hsa05322: Systemic lupus erythematosus 9 5.81E−07 HIST2H2AA3, HIST4H4, HIST1H2BC
hsa04670: Leukocyte transendothelial migration 6 1.89E−03 HIST2H2AA3, HIST4H4, HIST1H2BC
hsa04514: Cell adhesion molecules (CAMs) 6 3.10E−03 PECAM1, CLDN5, CLDN11
hsa04621: NOD-like receptor signaling pathway 4 1.15E−02 IL6, CCL2, NFKBIA, NLRP3
hsa04620: Toll-like receptor signaling pathway 4 4.15E−02 FOS, CCL3, IL6, NFKBIA
Table 3 Transcription factors (TFs) and tumor associated genes (TAGs) for genes in four clusters
TSG tumor suppress gene
TF TSG Oncogene Other
Cluster 1 ETV4, MSX2, PITX2, SMAD9 CUL7 KLK6
Cluster 2 CEACAM7, DEFB1, MUC1, SLC26A3
Cluster 3 EOMES, HEY2, HHEX, MEF2C, POU2AF1, STAT4, 
TCF21, TCF4
AIM2, BEX2, MAP4K1, PEG3, PRICKLE1, PYHIN1, 
TCF4
EVI2B
Cluster 4 ATF3, DBP, HAND1, KLF2, MAFB, SOX18 ZFP36 FOS CCL2, MAFB, RGS2, RHOB
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Table 4 The mircoRNAs (miRNAs) and their target genes
MiRNA Count P‑value Gene
Cluster 1 hsa-miR-382 3 5.77E−03 CLDN1, DLX3, IRX3
hsa-miR-217 4 1.11E−02 DMRT2, MSX2, SMAD9, VSNL1
hsa-miR-21 2 4.80E−02 PITX2, VSNL1
Cluster 3 hsa-miR-935 2 1.69E−02 EOMES, RELN
hsa-miR-1184 2 2.90E−02 TCF4, HEY2
hsa-miR-326 6 3.02E−02 TCF4, C16orf45, HLA-DOA, PKIA, PTGIS, SPOCK1
hsa-miR-496 5 3.45E−02 RASGRP3, ARHGEF6, MOXD1, PEG3, PTGIS
hsa-miR-330-5p 5 4.22E−02 TCF4, C16orf45, HLA-DOA, PKIA, SPOCK1
Cluster 4 hsa-miR-338-5p 6 8.35E−04 EBF3, KLF2, LDB2, NRP1, SLIT3, VEGFC
hsa-miR-656 4 6.96E−03 COLEC12, DUSP1, TEK, ZFP36
hsa-miR-30d 9 1.08E−02 CYYR1, EBF3, EMCN, GFPT2, NRP1, RGS2, RHOB, RRAD, ZNF521
hsa-miR-30b 9 1.10E−02 CYYR1, EBF3, EMCN, GFPT2, NRP1, RGS2, RHOB, RRAD, ZNF521
hsa-miR-30a 9 1.11E−02 CYYR1, EBF3, EMCN, GFPT2,NRP1, RGS2, RHOB, RRAD, ZNF521
hsa-miR-30c 9 1.12E−02 CYYR1, EBF3, EMCN, GFPT2, NRP1, RGS2, RHOB, RRAD, ZNF521
hsa-miR-30e 9 1.12E −02 CYYR1, EBF3, EMCN, GFPT2, NRP1, RGS2, RHOB, RRAD, ZNF521
hsa-miR-300 10 2.79E−02 EBF3, IER5, LDB2, MMRN1, NFKBIA, NRP1, SELE, TEK, ZFP36, ZNF521
hsa-miR-27a 6 4.69E−02 CDH5, EBF3, GEM, GFPT2, RGS1, VEGFC
hsa-miR-27b 6 4.73E−02 CDH5, EBF3, GEM, GFPT2, RGS1, VEGFC
Fig. 2 The protein–protein interaction (PPI) of genes in cluster 1 (a), cluster 2 (b), cluster 3 (c) and cluster 4 (d). Green and red nodes represent genes 
that were decreased and increased, respectively. The different outer rings indicate genes in different clusters
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complex, through its control over c-MYC and p21 activity, 
inhibits the differentiation on CRC cells [31]. Li et al. [32] 
found that miR-1184 was down-regulated and might play 
an important role in rectal cancer. Chen et al [33] reported 
that miR-326 was abnormally expressed in CRC and could 
be used as a novel biomarker for diagnosis of the cancer. 
Lin et  al [34] showed that miR-330-5p was dysregulated 
in CRC with liver metastasis. In addition, TCF4 also regu-
lates another TF in Int-c3 network, MEF2C, which could 
modulate 17 genes in cluster 3. MEF2C is a TF in the MEF2 
family and involved in cardiac morphogenesis, myogenesis 
and vascular development. MEF2 has been shown to have 
a significant role in angiogenesis [35], and proven to be 
over-expressed in hepatocellular carcinoma [36]. Although 
there was little research mentioned that C16orf45 and RAS-
GRP3 were directly associated with CRC, our results sug-
gested miR-1184, miR-326 and miR-330-5p were involve in 
CRC by interacting with TCF4, C16orf45 and RASGRP3. 
Therefore, it might be inferred that TCF4, C16orf45 and 
RASGRP3, mediated by these miRNAs, might play impor-
tant roles in the CRC progression and be used as the thera-
peutic targets. The predicted regulation of TCF4 and three 
miRNAs, miR-1184, miR-326 and miR-330-5p, will be vali-
dated in our further studies.
FOS, the hub node in the PPI network 4, is proved to be 
a TF and regulate 43 genes in cluster 4. FOS is found to 
interact with JUN (jun proto-oncogene, c-JUN) to form 
the transcription factor AP-1 (activating protein 1) that 
is crucial for cell adaptation to environmental changes 
[37, 38]. Meanwhile, Musella et  al. [14] also have found 
that JUN is a critical time-related gene in CRC. AP-1 reg-
ulates the expression of multiple genes essential for cell 
differentiation, proliferation, and apoptosis and plays an 
important role in various human diseases such as CRC 
[39]. Therefore, our results suggested that the increase 
of FOS may play important role in the period of CRC 
patients after surgery.
However, there are some limitations in our study. First, 
we mainly analyzed the relationships among genes and 
miRNAs in the same cluster. The regulatory relationships 
among molecules in different clusters and the interac-
tions between clusters are needed further explored. Sec-
ond, substantial experimental validations of the predicted 
miRNA-target relationships are warranted to confirm our 
results. Nevertheless, our results are still of great value to 
provide clues for further studies focusing on roles of sev-
eral special miRNAs, such as miR-21, -1184, -330-5p and 
-326 in CRC progression.
Conclusions
In summary, a set of genes and the related TFs and 
miRNAs were screened by analyzing of time course 
gene expression in CRC tissues. Our findings suggested 
that expression of genes such as PITX2, VSNL1, TCF4, 
MEF2C and FOS, are time-related. Meanwhile, miRNAs 
such as miR-382, miR-217, miR-21, miR-1184, miR-326 
and miR-330-5p might be involved in the progression of 
CRC. All the genes and miRNAs might be used as poten-
tial diagnostic and/or therapeutic target molecules for 
CRC.
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